THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells

Leukemia Research

Volumn 23, Issue 10, 1999, Pages 865-870

  Bremner, Theodore A ^a   Chatterjee, Devasis ^b   Han, Zhiyong ^b   Tsan, Min Fu ^c   Wyche, James H ^b  

^a HOWARD UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c STRATTON VA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Fas; Fas ligand; Lipopolysaccharide; Phorbol ester

Indexed keywords

FAS LIGAND;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MACROPHAGE; PRIORITY JOURNAL;

ANTIGENS, CD95; APOPTOSIS; CELL COMMUNICATION; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; HL-60 CELLS; HUMANS; JURKAT CELLS; LEUKEMIA, MONOCYTIC, ACUTE; MEMBRANE GLYCOPROTEINS; MONOCYTES; T-LYMPHOCYTES;

EID: 0032877432     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00101-0     Document Type: Article

References (40)

1. Nagata S., Goldstein P. The Fas death factor. Science. 267:1995;1449.
2. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science. 276:1997;111.
3. Alderson M.R., Tough T.W., Davis-Smith T., Braddy S., Falk B., Schooley K.A., Goodwin R.G., Smith C.A., Ramsdell K., Lynch D.H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:1995;71.
4. Krammer P.H., Dhein J., Walczak H., Behrman I., Mariani S., Matiba B., Fath M. et al. The role of APO-1-mediated apoptosis in the immune system. Immunol. Rev. 142:1994;175.
5. Russell J.H., Wang R. Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T-cells. Eur. J. Immunol. 23:1993;2379.
6. Singer G.G., Carrera A.C., Marshak-Rothstein A., Martínez C., Abbas A.K. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr. Opin. Immunol. 6:1994;913.
7. Ellis R.E., Yuan J., Horvitz H.R. Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 7:1991;663.
8. Raff M.C., Barnes B.A., Burne J.F., Coles H.S., Ishizaki Y., Jacobson M.D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 262:1993;695.
9. Tschopp J., Hofmann K. Cytotoxic T-cells: more weapons for new targets? Trends Microbiol. 4:1996;91.
10. Tanaka M., Suda T., Takahashi T., Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1995;1129.
11. Mariani S.M., Matiba B., Bäumler C., Krammer P.H. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25:1995;2303.
12. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1995;1777.
13. Boldin M.P., Varfolomeev E.E., Pancer Z., Mett I.L., Camonis J.H., Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270:1995;7795.
14. Chinnaiyan A.M., O'Rourke K., Tewari M., Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:1995;505.
15. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell. 87:1996;171.
16. Zhang J., Cado D., Chen A., Cabra N.H., Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 392:1998;296.
17. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 85:1996;803.
18. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., Peter M.E. Cytotoxicity-dependent Apo-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:1995;5579.
19. Martin S.J., Green D.R. Protease activation during apoptosis: death by a thousand cuts. Cell. 82:1995;349.
20. Dou Q.P., An B., Antoku K., Johnson D.E. Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J. Cell Biochem. 64:1997;586.
21. Peng S.L., Robert M.E., Hayday A.C., Craft J. A tumor suppressor function for Fas (CD95) revealed in T-cell deficient mice. J. Exp. Med. 184:1996;1149.
22. Tollefson A.E., Hermiston T.W., Lichtenstein D.L., Colle C.F., Tripp R.A., Dimitrov T., Toth K., Wells C.E., Doherty P.C., Wold W.S.M. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature. 392:1998;726.
23. Kondo T., Suda T., Fukuyama H., Adachi M., Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med. 3:1997;409.
24. Giordano C., Stassi G., De Maria R., Todaro M., Richiusa P., Papoff G., Ruberti G., Bagnasco M., Testi R., Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 275:1996;960.
25. Chervonsky A.V., Wang Y., Wong F.S., Visintin I., Flavell R.A., Janeway Jr C.A., Matis L.A. The role of Fas in autoimmune diabetes. Cell. 89:1997;17.
26. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - A mechanism of tumor evasion? Nature Med. 2:1996;1361.
27. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J.-C., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363.
28. Kiener P.A., Davis P.M., Rankin B.M., Klebanoff S.J., Ledbetter J.A., Starling G.C., Liles W.C. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J. Immunol. 159:1997;1594.
29. + T-cells apoptosis. J. Immunol. 158:1997;2456-2463.
30. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 185:1997;55.
31. Kizaki M., Koeffler H.P., Lin C.-W., Miller C.W. Expression of retinoic acid receptor mRNA in hematopoietic cells. Leuk. Res. 14:1990;645.
32. L. Cancer Res. 56:1996;1621.
33. Asseffa A., Dickson L.A., Mohla S., Bremner T.A. Phorbol myristate acetate-differentiated THP-1 cells display increased levels of MHC class I and class II mRNA and interferon-γ-inducible tumoricidal activity. Oncol. Res. 5:1993;11.
34. Laemmli U.K. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature. 227:1970;680.
35. Oyaizu N., Kayagaki N., Yagita H., Pahwa S., Ikawa Y. Requirement of cell-cell contact in the induction of Jurkat T-cell apoptosis: the membrane anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T-cells. Biochem. Biophys. Res. Commun. 238:1997;670.
36. Möller P., Koretz K., Leithäuser F., Brüderlein S., Henne C., Quentmeier A., Krammer P.H. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer. 57:1994;371-377.
37. Bouscary D., De Vos J., Guesnu M., Jondeau K., Viguier F., Melle J., Picard F., Dreyfus F., Fontenay-Roupie M. Fas/Aps-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 11:1997;839.
38. Dirks W., Schöne S., Uphoff C., Quentmeier H., Pradella S., Drexler H.G. Expression and function of CD95 (Fas/APO-1) in leukaemia-lymphoma tumor lines. Br. J. Hematol. 96:1997;584.
39. Nagata S. Fas ligand and immune evasion. Nature Med. 2:1996;1306.
40. Haziot A., Ferrero E., Köntgen F., Hijiya N., Yamamoto S., Silver J., Stewart C.L., Goyert S.M. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity. 4:1996;407.